Ferron G M, Jusko W J
Department of Pharmaceutics, State University of New York at Buffalo, USA.
Pharm Res. 1998 Dec;15(12):1888-94. doi: 10.1023/a:1011966308791.
To assess pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone (Pred, I1 mg/kg) and sirolimus (Sir, 0.25 mg/kg) in rabbits.
After intravenous administration, plasma concentrations of Pred and corticosterone, and Sir blood concentrations were followed for 24 hours along with blood granulocyte and T-helper cell counts. Ex vivo and in vitro whole blood lymphocyte proliferation marked lymphocyte reactivity.
Pred terminal half-life and clearance were 1.1 hr and 0.72 l/hr/kg with no difference after Sir. Sir values were 13 hr and 0.16 l/hr/kg and Pred produced no changes. Corticosterone production (0-12hr) was suppressed by 55% after Pred alone or combined, while Sir did not cause adrenal suppression. Blood T-helper cells and granulocytes displayed circadian rhythms after placebo. Over 12 hr, T-helper cell counts were decreased by Pred (40%) and Sir (19%) while granulocyte numbers increased by 56% and 23%. After coadministration, cell numbers were similar to Pred alone. Pred and Sir decreased lymphocyte reactivity by 41% and 56% over 24 hr and their combination reached 85% inhibition with additive interaction. In vitro studies showed antagonistic or synergistic interactions depending on drug concentration ratios.
At therapeutic concentrations, Sir and Pred do not significantly interact pharmacokinetically and have additive pharmacoimmunodynamics. Thus, the therapeutic application of this combination is promising.
评估泼尼松龙(Pred,1mg/kg)与西罗莫司(Sir,0.25mg/kg)在兔体内的药代动力学和药物免疫动力学相互作用。
静脉给药后,监测Pred和皮质酮的血浆浓度、Sir的血药浓度24小时,同时监测血液中粒细胞和辅助性T细胞计数。体外和体内全血淋巴细胞增殖标记淋巴细胞反应性。
Pred的终末半衰期和清除率分别为1.1小时和0.72L/小时/千克,给予Sir后无差异。Sir的值分别为13小时和0.16L/小时/千克,Pred未产生变化。单独或联合使用Pred后,皮质酮生成(0 - 12小时)被抑制55%,而Sir未引起肾上腺抑制。安慰剂组后血液辅助性T细胞和粒细胞呈现昼夜节律。在12小时内,Pred(40%)和Sir(19%)使辅助性T细胞计数减少,而粒细胞数量分别增加56%和23%。联合给药后,细胞数量与单独使用Pred时相似。Pred和Sir在24小时内使淋巴细胞反应性分别降低41%和56%,两者联合达到85%抑制,呈相加相互作用。体外研究显示根据药物浓度比存在拮抗或协同相互作用。
在治疗浓度下,Sir和Pred在药代动力学上无显著相互作用,且具有相加的药物免疫动力学。因此,该联合用药的治疗应用前景良好。